Does cigarette smoking increase plasma urotensin II concentrations?

No abstract is available for this paper.

• Publication year

  2007

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  2007-01-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00228-006-0252-6PMID 17252242
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Involvement of cyclooxygenase-dependent pathway in contraction of isolated ileum by urotensin II.

  2005cited by this paper
• Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade.

  2005cited by this paper
• Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: a pilot study.

  2005cited by this paper
• Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension.

  2005cited by this paper
• Urotensin II: Its Function in Health and Its Role in Disease

  2005cited by this paper
• Urotensin II: the old kid in town.

  2004cited by this paper
• From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function.

  2004cited by this paper
• Urotensin-II and the cardiovascular system – the importance of developing modulators

  2004cited by this paper
• Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease.

  2004cited by this paper
• Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain.

  2004influential reference
• Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure

  2004cited by this paper
• Increased plasma urotensin II levels in patients with diabetes mellitus.

  2003cited by this paper
• Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions

  2003cited by this paper
• Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

  2003cited by this paper
• A Comparison of Cerebrospinal Fluid and Plasma Urotensin II Concentrations in Normotensive and Hypertensive Patients Undergoing Urological Surgery During Spinal Anesthesia: A Pilot Study

  2003cited by this paper
• Central cardiovascular action of urotensin II in conscious rats

  2003cited by this paper
• Is urotensin‐II the new endothelin?

  2002cited by this paper
• Non-competitive immunochemiluminometric assay for cardiotrophin-1 detects elevated plasma levels in human heart failure.

  2002cited by this paper
• Plasma Urotensin in Human Systolic Heart Failure

  2002cited by this paper
• Non-competitive immunochemiluminometric assay for cardiotrophin-I detects elevated plasma levels in human heart failure

  2002cited by this paper
• Role of urotensin II in patients on dialysis.

  2001cited by this paper
• Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues

  2001cited by this paper
• Orphan‐receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin‐1

  2000cited by this paper
• Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries.

  2000cited by this paper
• Urotensin II: fish neuropeptide catches orphan receptor.

  2000cited by this paper
• Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

  2000cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Increased plasma endothelin-1 after nicotine consumption in nonsmokers.

  1997cited by this paper
• Association of serum low density lipoprotein cholesterol, smoking and hypertension with different manifestations of atherosclerosis.

  1990cited by this paper
• Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction.

  1988cited by this paper
• Cigarette smoking in hypertensive patients. Blood pressure and endocrine responses.

  1985cited by this paper
• A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts.

  1969cited by this paper

• Plasma urotensin-2 levels as a potential biomarker in prostate cancer: Analysis across disease stages

  2025cites this paper
• The Association of Passive Smoking and Serum Urotensin-II Levels in Children.

  2022cites this paper
• Effects of Varenicline on Cardiovascular Parameters and Oxidative Stress

  2017cites this paper
• Physiological Importance of Endothelium

  2013cites this paper
• Cisplatin and paclitaxel have differing effects on oxidative stress and mitochondrial function in dorsal root ganglion cells

  2013cites this paper
• Role of urotensin II in health and disease.

  2010cites this paper
• Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases.

  2009cites this paper
• Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia.

  2009cites this paper
• Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease.

  2009cites this paper
• Nociceptin and urotensin-II concentrations in critically ill patients with sepsis.

  2008cites this paper
• The Urotensin II System in Ischaemic Myocardial Dysfunction.

  2008influential citation
• Urotensin II in cardiovascular regulation

  2008influential citation
• The role of urotensin II in the metabolic syndrome.

  2008cites this paper
• Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes.

  2008cites this paper